SignalUS

Drug discontinuation: Mesalamine Capsule, Extended Release (MESALAMINE)

FDA lists 3 presentations as To Be Discontinued. Companies: Mylan Pharmaceuticals Inc., a Viatris Company, Takeda Pharmaceuticals USA Inc..

Published by source
2026-08-25
First seen by Reality Radar
2026-10-22
Last verified
2026-10-28

Affected

Manufacturer
Mylan Pharmaceuticals Inc., a Viatris Company
Products
Mesalamine Capsule, Extended Release MESALAMINE

Whether your exact unit is affected depends on the model, serial number and region in the official notice.

What the official notice says

Risk: To Be Discontinued

Remedy / actions:

  • Discontinuation of the manufacture of the drug
  • Product is anticipated to be available until December 31, 2027

Is this affecting you?

Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.

Track it free

Sources

Evidence ledger

Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.

EntryKindObservedEvidence hashEntry hash
#982new2026-10-226ee00cd3472d…1668c0b453f3ac5a87…39026c
#1207update2026-10-23a7e63e8110da…2490329882ddc82784…b6f806
#1479update2026-10-236ee00cd3472d…1668c0ad3417dbc128…777bd4
#2184update2026-10-27fe856f7c3668…1c82f0d5bef2c5a567…a8686d
#2592update2026-10-28be52264d61f3…98ffcb2d485b60a4cc…760e93

Chain head: #2644 26bcb516f5ea…c4392a

Raw ledger entries (JSON) · Verify chain

Share this signal